PG
北極星藥業集團股份有限公司
PG is a Taiwan TWSE-listed biotechnology company; its most advanced asset is ADI-PEG 20 (Phase 2; active not recruiting, Glioblastoma Multiforme (GBM)), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| ADI-PEG 20 | — | Phase 2; active not recruiting | Glioblastoma Multiforme (GBM) | South Korea, Taiwan | 2025-08-26 | Trial registry |
Key events
- Business update (company filing)
- Business update (company filing)
- Business update (company filing)
Related Drugnews articles
No related articles in this language.